セキ　マサフミ   SEK Masafumi   関　雅文    所属   埼玉医科大学  医学部 国際医療センター　感染症科・感染制御科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
掲載誌名	正式名：The Journal of antimicrobial chemotherapy
巻・号・頁	62(6),1326-31頁
著者・共著者	Yoshitomo Morinaga,Katsunori Yanagihara,Shigeki Nakamura,Kazuko Yamamoto,Koichi Izumikawa,Masafumi Seki,Hiroshi Kakeya,Yoshihiro Yamamoto,Yasuaki Yamada,Shigeru Kohno,Shimeru Kamihira
発行年月	2008/12
概要	OBJECTIVES: Tomopenem(CS-023) is a novel parenteral carbapenem with broad-spectrum activity against Gram-positive and -negative bacteria, as well as potent activity against drug-resistant pathogens, including penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. We compared the in vivo activity of tomopenem and that of meropenem in a chronic lower respiratory infection mouse model of P. aeruginosa. METHODS: Mice with chronic airway infection by P. aeruginosa were treated with saline (as the control, twice daily), tomopenem (100 mg/kg, twice daily) or meropenem (100 mg/kg, twice daily) for 7 days. After treatment, the number of viable bacteria in lungs and histopathological findings were analysed. The pharmacokinetics of tomopenem and meropenem were also analysed after initial treatment. RESULTS: The number of viable bacteria in lungs treated with saline, tomopenem or meropenem was 4.21 +/- 1.28, 2.91 +/- 0.87 and 3.01 +/- 1.00 log(10) cfu/lung (mean +/- SEM), respectively (P<0.05, control versus tomopenem- or meropenem-treated groups). In the histopathological examination of lung specimens, the control group had th
DOI	10.1093/jac/dkn411
PMID	18835805